Barely 3 months a public company, Dicerna has yet to emerge
as a distinct RNAi Therapeutics player similar to the likes of Alnylam (à subQ GalNAc),
Arrowhead Research (receptor-targeted DPCs), and Tekmira (àhigh potency liposomal
RNAi). Without leveraging the potential advantages of its Dicer-substrate RNAi triggers
on which it had been founded, Dicerna will be remembered by the market as not much more than an IP workaround play.
Currently, Dicerna is utilizing liposomal delivery for its lead
programs in cancer and orphan disease primary hyperoxaluria 1 (PH1), a highly versatile approach, but a niche that might be better left to Tekmira. At least for the greater good of RNAi Therapeutics investment dollars.
Instead, Dicerna should compete more directly with both
Alnylam and Arrowhead in conjugate delivery. This is because Dicer substrates allow for
the liberation of the active small interfering RNA from the conjugated ligand
and/or polymer backbone by Dicer directly chewing off the conjugate. By contrast, for conjugates like current
GalNAc-siRNAs or DPCs, removal of the ligand/backbone has to be accomplished
via more complex or difficult-to-work-with linker chemistries including protease-sensitive
linkers or disulfides. Such removal is
usually necessary to allow for efficient incorporation into the RNAi effector
complex RISC.
In fact, it may be this chemical attachment challenge that
has delayed Arrowhead’s single-molecule DPCs which I am so keen seeing progress
into the clinic.
Of course, similar to adopting liposomal delivery, becoming
expert in conjugate delivery probably won’t happen overnight and requires
the hiring of appropriate talent.
Competition for such talent ought to be fierce with both Arrowhead and and particularly hometown rival Alnylam well cashed up and even antisense company ISIS entering the field.
We have now well crossed the point that RNAi Therapeutics is
ready to churn out drugs. If each of
the players were to focus on its core strengths, it would ensure that the reach of the technology will grow in a most efficient manner.
No comments:
Post a Comment